Emcure Pharma rises 4% on CDSCO approval for MASH drug

Emcure Pharmaceuticals received CDSCO approval to expand Poviztra® (semaglutide) for treatment of MASH in adults with moderate to advanced liver fibrosis (F2-F3).

Poviztra® is the first GLP-1 receptor agonist approved in India for MASH, based on the global Phase III ESSENCE trial where semaglutide achieved steatohepatitis resolution in 63% of patients.

The approval addresses a significant unmet medical need as MASH is a progressive liver disease associated with obesity and type 2 diabetes.

Emcure’s CEO Satish Mehta stated the expansion strengthens the company's commitment to bringing innovative therapies to Indian patients with metabolic diseases.

Poviztra® was already approved for chronic weight management and adolescent obesity, and the MASH indication further broadens Emcure's metabolic care portfolio.